{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:04:50Z","timestamp":1791907490616,"version":"4.3.4"},"reference-count":174,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Rep"],"DOI":"10.3892\/or.2026.9093","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:31:21Z","timestamp":1772789481000},"page":"1-19","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review)"],"prefix":"10.3892","volume":"55","author":[{"given":"Junlun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoren","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"key20260406110124_b1-or-55-5-09093","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.semcdb.2020.10.006","article-title":"Multiple myeloma-A painful disease of the bone marrow","volume":"112","author":"Diaz-delCastillo","year":"2021","journal-title":"Semin Cell Dev Biol"},{"key":"key20260406110124_b2-or-55-5-09093","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag030","article-title":"Differential life expectancies and life years lost associated with multiple myeloma in the United States: A simulation modelling study","author":"Michaud","year":"2026","journal-title":"Oncologist"},{"key":"key20260406110124_b3-or-55-5-09093","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"key20260406110124_b4-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in Urban area in China: A national population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"key20260406110124_b5-or-55-5-09093","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key20260406110124_b6-or-55-5-09093","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"key20260406110124_b7-or-55-5-09093","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/2643-3230.BCD-25-0328","article-title":"Acquired and selected: tracking antigen escape during T cell-redirecting therapies in multiple myeloma","volume":"6","author":"Kauer","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"key20260406110124_b8-or-55-5-09093","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/bloodadvances.2025017721","article-title":"Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection","volume":"10","author":"Sudha","year":"2026","journal-title":"Blood Adv"},{"key":"key20260406110124_b9-or-55-5-09093","first-page":"2139","article-title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: A frailty subgroup analysis of the IMROZ trial","volume":"110","author":"Manier","year":"2025","journal-title":"Haematologica"},{"key":"key20260406110124_b10-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): A phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier","year":"2025","journal-title":"Lancet Oncol"},{"key":"key20260406110124_b11-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3026(25)00143-7","article-title":"Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): A phase 3, open-label, multicentre, randomised clinical trial","volume":"12","author":"Mateos","year":"2025","journal-title":"Lancet Haematol"},{"key":"key20260406110124_b12-or-55-5-09093","doi-asserted-by":"publisher","first-page":"218245","DOI":"10.1016\/j.canlet.2026.218245","article-title":"The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism","volume":"640","author":"Tu","year":"2026","journal-title":"Cancer Lett"},{"key":"key20260406110124_b13-or-55-5-09093","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/biom15050702","article-title":"Post-translational modifications in multiple myeloma: Mechanisms of drug resistance and therapeutic opportunities","volume":"15","author":"Hu","year":"2025","journal-title":"Biomolecules"},{"key":"key20260406110124_b14-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e2415695","DOI":"10.1002\/advs.202415695","article-title":"Enhancer extrachromosomal circular DNA ANKRD28 elicits drug resistance via POU2F2-Mediated transcriptional network in multiple myeloma","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"key20260406110124_b15-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260406110124_b16-or-55-5-09093","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20260406110124_b17-or-55-5-09093","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-025-01268-y","article-title":"A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma","volume":"15","author":"Brieghel","year":"2025","journal-title":"Blood Cancer J"},{"key":"key20260406110124_b18-or-55-5-09093","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"key20260406110124_b19-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.3390\/cancers12113106","article-title":"Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients","volume":"12","author":"Bonello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b20-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege","year":"2020","journal-title":"Leukemia"},{"key":"key20260406110124_b21-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1200\/JOP.19.00208","article-title":"Integrating touchscreen-based geriatric assessment and frailty screening for adults with multiple myeloma to drive personalized treatment decisions","volume":"16","author":"Nathwani","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"key20260406110124_b22-or-55-5-09093","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/imj.16049","article-title":"The importance of frailty assessment in multiple myeloma: A position statement from the myeloma scientific advisory group to myeloma Australia","volume":"53","author":"Sim","year":"2023","journal-title":"Intern Med J"},{"key":"key20260406110124_b23-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","article-title":"How I treat high-risk multiple myeloma","volume":"139","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"key20260406110124_b24-or-55-5-09093","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/CCO.0000000000000792","article-title":"Geriatric assessments and frailty scores in multiple myeloma patients: A needed tool for individualized treatment?","volume":"33","author":"M\u00f6ller","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"key20260406110124_b25-or-55-5-09093","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12957-025-04007-6","article-title":"Sarcopenia and fat loss from serial CT predict survival in multiple myeloma patients undergoing stem cell transplantation","volume":"23","author":"Kylies","year":"2025","journal-title":"World J Surg Oncol"},{"key":"key20260406110124_b26-or-55-5-09093","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000549514","article-title":"Sarcopenia in older patients with newly diagnosed multiple myeloma","volume":"72","author":"Sobrini-Morillo","year":"2026","journal-title":"Gerontology"},{"key":"key20260406110124_b27-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jgo.2020.06.002","article-title":"Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists","volume":"11","author":"Jo\u00e3o","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"key20260406110124_b28-or-55-5-09093","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key20260406110124_b29-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"key20260406110124_b30-or-55-5-09093","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00432-019-03101-z","article-title":"Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: Final results of the German Maintenance Study (GERMAIN)","volume":"146","author":"Brioli","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20260406110124_b31-or-55-5-09093","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2174\/0115665232316769240912061652","article-title":"Identification of gene signatures associated with COVID-19 across children, adolescents, and adults in the nasopharynx and peripheral blood by using a machine learning approach","volume":"25","author":"Bao","year":"2025","journal-title":"Curr Gene Ther"},{"key":"key20260406110124_b32-or-55-5-09093","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/0115665232323373240905104033","article-title":"Characteristics of oxidative phosphorylation-related subtypes and construction of a prognostic signature in ovarian cancer","volume":"25","author":"Lu","year":"2025","journal-title":"Curr Gene Ther"},{"key":"key20260406110124_b33-or-55-5-09093","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"key20260406110124_b34-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"key20260406110124_b35-or-55-5-09093","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"Rockwood","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key20260406110124_b36-or-55-5-09093","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jgo.2020.09.031","article-title":"Electronic FRAIL score may predict treatment outcomes in older adults with myeloma","volume":"12","author":"Chan","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"key20260406110124_b37-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e13793","DOI":"10.1002\/jcsm.13793","article-title":"A Randomized Controlled \u2018REAL-FITNESS\u2019 trial to evaluate physical activity in patients with newly diagnosed multiple myeloma","volume":"16","author":"Dreyling","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key20260406110124_b38-or-55-5-09093","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1182\/blood.2024025868","article-title":"Beyond static measurements: Dynamic frailty improves survival prediction in multiple myeloma","volume":"145","author":"Smits","year":"2025","journal-title":"Blood"},{"key":"key20260406110124_b39-or-55-5-09093","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5582\/bst.2023.01204","article-title":"Healthy aging, early screening, and interventions for frailty in the elderly","volume":"17","author":"Deng","year":"2023","journal-title":"Biosci Trends"},{"key":"key20260406110124_b40-or-55-5-09093","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.18336","article-title":"Peripheral blood CD3(+) T-cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies","volume":"199","author":"Fell","year":"2022","journal-title":"Br J Haematol"},{"key":"key20260406110124_b41-or-55-5-09093","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10585-024-10305-2","article-title":"Multiple myeloma: Clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics","volume":"41","author":"Elbahoty","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"key20260406110124_b42-or-55-5-09093","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","article-title":"Multiple myeloma, a quintessential malignant disease of aging: A geroscience perspective on pathogenesis and treatment","volume":"45","author":"Urban","year":"2023","journal-title":"Geroscience"},{"key":"key20260406110124_b43-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.2217\/fon-2022-0933","article-title":"Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients","volume":"18","author":"Ran","year":"2022","journal-title":"Future Oncol"},{"key":"key20260406110124_b44-or-55-5-09093","first-page":"109","article-title":"Lifestyle-related factors and cancer incidence in men: A public health assessment based on a \u2018healthy lifestyle score\u2019","volume":"34","author":"Tang","year":"2013","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"key20260406110124_b45-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/nu12113367","article-title":"Nutrition management in older adults with diabetes: A review on the importance of shifting prevention strategies from metabolic syndrome to frailty","volume":"12","author":"Tamura","year":"2020","journal-title":"Nutrients"},{"key":"key20260406110124_b46-or-55-5-09093","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/nu13020641","article-title":"Low dietary variety and diabetes mellitus are associated with frailty among community-dwelling older Japanese adults: A cross-sectional study","volume":"13","author":"Hayakawa","year":"2021","journal-title":"Nutrients"},{"key":"key20260406110124_b47-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.2196\/jmir.3687","article-title":"Information and communication technology-enabled person-centered care for the \u2018big five\u2019 chronic conditions: scoping review","volume":"17","author":"Wildevuur","year":"2015","journal-title":"J Med Internet Res"},{"key":"key20260406110124_b48-or-55-5-09093","doi-asserted-by":"publisher","first-page":"105087","DOI":"10.1016\/j.archger.2023.105107","article-title":"Potentially inappropriate medication and frailty in older adults: A systematic review and meta-analysis","volume":"114","author":"Ma","year":"2023","journal-title":"Arch Gerontol Geriatr"},{"key":"key20260406110124_b49-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e2447605","DOI":"10.1001\/jamanetworkopen.2024.47605","article-title":"Psychological resilience and frailty progression in older adults","volume":"7","author":"Ye","year":"2024","journal-title":"JAMA Netw Open"},{"key":"key20260406110124_b50-or-55-5-09093","doi-asserted-by":"publisher","first-page":"102442","DOI":"10.1016\/j.arr.2024.102442","article-title":"Definition and assessment of psychological frailty in older adults: A scoping review","volume":"100","author":"Lameirinhas","year":"2024","journal-title":"Ageing Res Rev"},{"key":"key20260406110124_b51-or-55-5-09093","doi-asserted-by":"publisher","first-page":"102420","DOI":"10.1016\/j.arr.2024.102420","article-title":"Frailty and socioeconomic position: A systematic review of observational studies","volume":"100","author":"Hanlon","year":"2024","journal-title":"Ageing Res Rev"},{"key":"key20260406110124_b52-or-55-5-09093","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41375-023-01874-4","article-title":"Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders","volume":"37","author":"Shah","year":"2023","journal-title":"Leukemia"},{"key":"key20260406110124_b53-or-55-5-09093","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1017\/S0029665123004792","article-title":"Nutrition and immunity: Lessons from coronavirus disease-2019","volume":"84","author":"Calder","year":"2025","journal-title":"Proc Nutr Soc"},{"key":"key20260406110124_b54-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s11136-023-03390-5","article-title":"Measuring frailty using patient-reported outcomes (PRO) Data: A feasibility study in patients with multiple myeloma","volume":"32","author":"Murugappan","year":"2023","journal-title":"Qual Life Res"},{"key":"key20260406110124_b55-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s00277-020-04356-0","article-title":"Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program","volume":"100","author":"Nielsen","year":"2021","journal-title":"Ann Hematol"},{"key":"key20260406110124_b56-or-55-5-09093","first-page":"715","article-title":"Anemia, cardiovascular disease, and frailty in the older adult","volume":"38","author":"O'Neill","year":"2022","journal-title":"Can J Cardiol"},{"key":"key20260406110124_b57-or-55-5-09093","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s11912-024-01545-2","article-title":"Personalized treatment of multiple myeloma in frail patients","volume":"26","author":"Lipof","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"key20260406110124_b58-or-55-5-09093","first-page":"1956","article-title":"Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research","volume":"109","author":"Oerlemans","year":"2024","journal-title":"Haematologica"},{"key":"key20260406110124_b59-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/cancers17172904","article-title":"Comprehensive geriatric assessment of older patients with multiple myeloma: A prospective observational study","volume":"17","author":"Sobrini-Morillo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b60-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"key20260406110124_b61-or-55-5-09093","doi-asserted-by":"publisher","first-page":"afab211","DOI":"10.1093\/ageing\/afab211","article-title":"Comprehensive geriatric assessment in newly diagnosed older myeloma patients: A multicentre, prospective, non-interventional study","volume":"51","author":"Yao","year":"2022","journal-title":"Age Ageing"},{"key":"key20260406110124_b62-or-55-5-09093","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood-2024-209653","article-title":"IMWG frailty score-adjusted therapy delivery reduces the early mortality risk in newly diagnosed tne multiple myeloma: Results of the UK myeloma research alliance (UK-MRA) Myeloma XIV fitness trial","volume":"144","author":"Cook","year":"2024","journal-title":"Blood"},{"key":"key20260406110124_b63-or-55-5-09093","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-024-01569-y","article-title":"Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: A prospective study","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20260406110124_b64-or-55-5-09093","doi-asserted-by":"publisher","first-page":"102167","DOI":"10.1016\/j.eclinm.2023.102167","article-title":"Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial","volume":"63","author":"Groen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"key20260406110124_b65-or-55-5-09093","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.clml.2023.03.007","article-title":"Ixazomib versus placebo as postinduction maintenance therapy in newly diagnosed multiple myeloma patients: An analysis by age and frailty status of the TOURMALINE-MM4 study","volume":"23","author":"Bringhen","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260406110124_b66-or-55-5-09093","doi-asserted-by":"publisher","first-page":"114153","DOI":"10.1016\/j.ejca.2024.114153","article-title":"Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial","volume":"207","author":"Seefat","year":"2024","journal-title":"Eur J Cancer"},{"key":"key20260406110124_b67-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/S2666-7568(22)00172-6","article-title":"Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: A GIMEMA, multicentre, cross-sectional study","volume":"3","author":"Efficace","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"key20260406110124_b68-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3390\/diagnostics15233038","article-title":"Determinants of eligibility and timing of autologous transplantation in multiple myeloma: The role of R-MCI and diagnostic plasma cell Burden","volume":"15","author":"Candan","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"key20260406110124_b69-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3324\/haematol.2022.281489","article-title":"An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence","volume":"108","author":"Holler","year":"2023","journal-title":"Haematologica"},{"key":"key20260406110124_b70-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): A development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"key":"key20260406110124_b71-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"key":"key20260406110124_b72-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J"},{"key":"key20260406110124_b73-or-55-5-09093","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jgo.2015.03.003","article-title":"Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale","volume":"6","author":"Bonanad","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"key20260406110124_b74-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1103687","DOI":"10.3389\/fonc.2023.1103687","article-title":"Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"key20260406110124_b75-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jcsm.12502","article-title":"Muscle mass, strength, and physical performance predicting activities of daily living: A meta-analysis","volume":"11","author":"Wang","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"key20260406110124_b76-or-55-5-09093","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s12603-009-0214-7","article-title":"Validation of the Mini Nutritional Assessment short-form (MNA-SF): A practical tool for identification of nutritional status","volume":"13","author":"Kaiser","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"key20260406110124_b77-or-55-5-09093","doi-asserted-by":"publisher","first-page":"894","DOI":"10.6004\/jnccn.2017.0122","article-title":"Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer","volume":"15","author":"Guerard","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260406110124_b78-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2024014624","article-title":"Cumulative deficits frailty index and relationship status predict survival in multiple myeloma","volume":"9","author":"Abdallah","year":"2025","journal-title":"Blood Adv"},{"key":"key20260406110124_b79-or-55-5-09093","doi-asserted-by":"publisher","first-page":"S787","DOI":"10.1097\/01.HS9.0000846456.26633.e7","article-title":"P896: Development and validation of a frailty prediction model more suitable for multiple myeloma in Chinese patients: The TM frailty score","volume":"6","author":"Chen","year":"2022","journal-title":"Hemasphere"},{"key":"key20260406110124_b80-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1182\/blood-2023-184676","article-title":"Retrospective Analysis of Four Frailty Assessment Tools in Elderly Patients with Multiple Myeloma","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"key20260406110124_b81-or-55-5-09093","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12672-024-01305-5","article-title":"Selection determines therapeutic effects: A retrospective analysis of the application of different frailty tools in elderly patients with multiple myeloma","volume":"15","author":"Li","year":"2024","journal-title":"Discov Oncol"},{"key":"key20260406110124_b82-or-55-5-09093","doi-asserted-by":"publisher","first-page":"S6644","DOI":"10.1182\/blood-2023-185230","article-title":"Evaluating the effectiveness of risk adjustment using dynamic frailty assessment in treating newly diagnosed multiple myeloma in elderly patients","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"key":"key20260406110124_b83-or-55-5-09093","doi-asserted-by":"publisher","first-page":"S6690","DOI":"10.1182\/blood-2023-185230","article-title":"Efficacy analysis of ixazomib-based regimens based on dynamic frailty assessment in elderly and frail patients with newly diagnosed multiple myeloma","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"key":"key20260406110124_b84-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/j.clml.2025.09.007","article-title":"Changes in frailty categorization over one year among Real-World patients with multiple Myeloma: A Prospective Cohort Study (MFRAIL)","volume":"26","author":"Haider","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260406110124_b85-or-55-5-09093","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1182\/bloodadvances.2025017394","article-title":"Frail subgroups determine heterogeneous outcomes in older patients with NDMM: Long-term follow-up of the HOVON 143 trial","volume":"9","author":"Smits","year":"2025","journal-title":"Blood Adv"},{"key":"key20260406110124_b86-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/bjh.70068","article-title":"Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study","volume":"207","author":"Tolosa-Ridao","year":"2025","journal-title":"Br J Haematol"},{"key":"key20260406110124_b87-or-55-5-09093","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"key20260406110124_b88-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2147\/OTT.S300834","article-title":"Evaluation of the UK myeloma research alliance risk profile in Chinese patients with newly diagnosed multiple myeloma without autologous stem cell transplantation","volume":"14","author":"Ma","year":"2021","journal-title":"Onco Targets Ther"},{"key":"key20260406110124_b89-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2558127","DOI":"10.1080\/07853890.2025.2558127","article-title":"Combining IMWG GA and hematopoietic score to optimize the evaluation of dynamic chemotherapy tolerance in multiple myeloma","volume":"57","author":"Chen","year":"2025","journal-title":"Ann Med"},{"key":"key20260406110124_b90-or-55-5-09093","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40001-025-03417-2","article-title":"Development and validation of a novel frailty model for the patients with newly diagnosed multiple myeloma","volume":"31","author":"Tian","year":"2025","journal-title":"Eur J Med Res"},{"key":"key20260406110124_b91-or-55-5-09093","doi-asserted-by":"publisher","first-page":"22907","DOI":"10.1038\/s41598-021-02433-6","article-title":"Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"key20260406110124_b92-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International staging system for multiple myeloma: A report from International myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20260406110124_b93-or-55-5-09093","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"key20260406110124_b94-or-55-5-09093","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4143\/crt.2025.066","article-title":"Validating the Korean geriatric assessment tool in elderly multiple myeloma patients: A multicenter study","volume":"58","author":"Lee","year":"2026","journal-title":"Cancer Res Treat"},{"key":"key20260406110124_b95-or-55-5-09093","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.jgo.2025.102266","article-title":"Assessing frailty in patients with relapsed\/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International myeloma working group frailty index","volume":"16","author":"Krepper","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"key20260406110124_b96-or-55-5-09093","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/cancers17050789","article-title":"Prognostic frailty-based determinants of long-term mortality in older patients with newly diagnosed multiple myeloma","volume":"17","author":"Muzyka","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b97-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3390\/cancers15133469","article-title":"The real-world evidence on the fragility and its impact on the choice of treatment regimen in newly diagnosed patients with multiple myeloma over 75 years of age","volume":"15","author":"Tyczy\u0144ska","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b98-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e247039","DOI":"10.6004\/jnccn.2024.7039","article-title":"Up-front treatment of elderly (Age \u226575 Years) and frail patients with multiple myeloma","volume":"22","author":"Abdallah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260406110124_b99-or-55-5-09093","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/10600280221087218","article-title":"Estimation of kidney function in patients with multiple myeloma: Implications for lenalidomide dosing","volume":"57","author":"Salama","year":"2023","journal-title":"Ann Pharmacother"},{"key":"key20260406110124_b100-or-55-5-09093","doi-asserted-by":"publisher","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN Guidelines\u00ae Insights: multiple myeloma, version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260406110124_b101-or-55-5-09093","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","volume":"39","author":"Mina","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20260406110124_b102-or-55-5-09093","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1182\/bloodadvances.2023011019","article-title":"More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]","volume":"7","author":"DuMontier","year":"2023","journal-title":"Blood Adv"},{"key":"key20260406110124_b103-or-55-5-09093","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/cancers17060944","article-title":"Challenges in multiple myeloma therapy in older and frail patients","volume":"17","author":"Aureli","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b104-or-55-5-09093","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"key20260406110124_b105-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: Validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"key20260406110124_b106-or-55-5-09093","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3324\/haematol.2020.254235","article-title":"Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial","volume":"106","author":"Dold","year":"2021","journal-title":"Haematologica"},{"key":"key20260406110124_b107-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"key20260406110124_b108-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e70210","DOI":"10.1002\/hem3.70210","article-title":"Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels","volume":"9","author":"Bruins","year":"2025","journal-title":"Hemasphere"},{"key":"key20260406110124_b109-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m(2) versus melphalan 100 mg\/m(2) in newly diagnosed myeloma patients: A prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"key20260406110124_b110-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.bbmt.2016.03.021","article-title":"Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20260406110124_b111-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41409-020-01170-0","article-title":"Melphalan 200 mg\/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients","volume":"56","author":"Brioli","year":"2021","journal-title":"Bone Marrow Transplantation"},{"key":"key20260406110124_b112-or-55-5-09093","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00277-023-05511-z","article-title":"Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: Upfront transplant with MEL200 remains the standard of care","volume":"103","author":"Bostankolu De\u011firmenci","year":"2024","journal-title":"Ann Hematol"},{"key":"key20260406110124_b113-or-55-5-09093","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ejh.13690","article-title":"Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma","volume":"107","author":"Straka","year":"2021","journal-title":"Eur J Haematol"},{"key":"key20260406110124_b114-or-55-5-09093","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"key20260406110124_b115-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20260406110124_b116-or-55-5-09093","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"key20260406110124_b117-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"key":"key20260406110124_b118-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/j.clml.2020.09.010","article-title":"Burden of treatment among older adults with newly diagnosed multiple myeloma","volume":"21","author":"Mian","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260406110124_b119-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): A multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol"},{"key":"key20260406110124_b120-or-55-5-09093","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"key":"key20260406110124_b121-or-55-5-09093","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): Final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"key":"key20260406110124_b122-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e066467","DOI":"10.1136\/bmjopen-2022-066467","article-title":"Classification of symptom subtypes in patients with multiple myeloma during treatment: A cross-sectional survey study in China","volume":"13","author":"Yu","year":"2023","journal-title":"BMJ Open"},{"key":"key20260406110124_b123-or-55-5-09093","doi-asserted-by":"publisher","first-page":"612696","DOI":"10.3389\/fmed.2021.612696","article-title":"Approaches and challenges in the management of multiple myeloma in the very old: Future treatment prospects","volume":"8","author":"Kaweme","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"key20260406110124_b124-or-55-5-09093","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ejh.13349","article-title":"The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"104","author":"Okazuka","year":"2020","journal-title":"Eur J Haematol"},{"key":"key20260406110124_b125-or-55-5-09093","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"key20260406110124_b126-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"key20260406110124_b127-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"key20260406110124_b128-or-55-5-09093","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ageing\/afx157","article-title":"Frailty and healthcare costs-longitudinal results of a prospective cohort study","volume":"47","author":"Hajek","year":"2018","journal-title":"Age Ageing"},{"key":"key20260406110124_b129-or-55-5-09093","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.3390\/cancers13235886","article-title":"Stratification for RRMM and risk-adapted therapy: Sequencing of therapies in RRMM","volume":"13","author":"Jeryczynski","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b130-or-55-5-09093","doi-asserted-by":"publisher","first-page":"36","DOI":"10.46989\/001c.133682","article-title":"Consensus guidelines and recommendations for the anti-CD38-based therapy in clinical practice for relapsed\/refractory multiple myeloma: From the Pan-Pacific multiple myeloma working group","volume":"7","author":"Chen","year":"2025","journal-title":"Clin Hematol Int"},{"key":"key20260406110124_b131-or-55-5-09093","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/jcm15010286","article-title":"Ixazomib-lenalidomide-dexamethasone for the treatment of relapsed\/refractory multiple myeloma: A hungarian real-world analysis","volume":"15","author":"S\u00e1nta","year":"2025","journal-title":"J Clin Med"},{"key":"key20260406110124_b132-or-55-5-09093","doi-asserted-by":"publisher","first-page":"101681","DOI":"10.1016\/j.jgo.2023.101681","article-title":"Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty","volume":"15","author":"Murugappan","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"key20260406110124_b133-or-55-5-09093","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"key20260406110124_b134-or-55-5-09093","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/bloodadvances.2025015973","article-title":"Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"9","author":"Adegbite","year":"2025","journal-title":"Blood Adv"},{"key":"key20260406110124_b135-or-55-5-09093","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clml.2023.10.009","article-title":"Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A Subanalysis of OPTIMISMM by frailty and bortezomib dose adjustment","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260406110124_b136-or-55-5-09093","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12185-024-03904-y","article-title":"Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed\/refractory multiple myeloma in Japan","volume":"121","author":"Tagami","year":"2025","journal-title":"Int J Hematol"},{"key":"key20260406110124_b137-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/cancers16091689","article-title":"A simple frailty score predicts survival and early mortality in systemic AL amyloidosis","volume":"16","author":"R\u00edos-Tamayo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"key20260406110124_b138-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"key20260406110124_b139-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/eurheartj\/ehad335","article-title":"NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial","volume":"44","author":"Adamo","year":"2023","journal-title":"Eur Heart J"},{"key":"key20260406110124_b140-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e032254","DOI":"10.1161\/JAHA.123.032254","article-title":"Longitudinal NT-proBNP: Associations with echocardiographic changes and outcomes in heart failure","volume":"13","author":"Teramoto","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"key20260406110124_b141-or-55-5-09093","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1186\/s12877-025-06699-7","article-title":"Untangling the prognostic value of diastolic dysfunction, NT-proBNP, and frailty in older patients with preserved left ventricular ejection fraction without valvular disease","volume":"25","author":"de Terwangne","year":"2025","journal-title":"BMC Geriatr"},{"key":"key20260406110124_b142-or-55-5-09093","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jgo.2021.12.004","article-title":"Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma","volume":"13","author":"Giri","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"key20260406110124_b143-or-55-5-09093","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10428194.2022.2136946","article-title":"Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation","volume":"64","author":"Mikulski","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"key20260406110124_b144-or-55-5-09093","doi-asserted-by":"publisher","first-page":"8100","DOI":"10.3390\/ijms23158100","article-title":"C-Reactive Protein Velocity (CRPv) as a new biomarker for the early detection of acute infection\/inflammation","volume":"23","author":"Levinson","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20260406110124_b145-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1612703","DOI":"10.3389\/fimmu.2025.1612703","article-title":"C-reactive protein: The nexus between inflammation and protein misfolding diseases","volume":"16","author":"Roy","year":"2025","journal-title":"Front Immunol"},{"key":"key20260406110124_b146-or-55-5-09093","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.3390\/ijms26146855","article-title":"The pathogenic role of C-Reactive protein in diabetes-linked unstable atherosclerosis","volume":"26","author":"Sibianu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"key20260406110124_b147-or-55-5-09093","doi-asserted-by":"publisher","first-page":"885516","DOI":"10.3389\/fendo.2022.885516","article-title":"Association between high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes mellitus","volume":"13","author":"Tang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20260406110124_b148-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1002\/edm2.400","article-title":"Association between Pro-oxidant-Antioxidant balance and high-sensitivity C-reactive protein in type 2 diabetes mellitus: A Study on Postmenopausal Women","volume":"6","author":"Ehteram","year":"2023","journal-title":"Endocrinol Diabetes Metab"},{"key":"key20260406110124_b149-or-55-5-09093","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-023-01830-7","article-title":"Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes","volume":"22","author":"Guo","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"key20260406110124_b150-or-55-5-09093","doi-asserted-by":"publisher","first-page":"3362336","DOI":"10.1155\/2024\/3362336","article-title":"C-Reactive protein level as a novel serum biomarker in sarcopenia","volume":"2024","author":"Lin","year":"2024","journal-title":"Mediators Inflamm"},{"key":"key20260406110124_b151-or-55-5-09093","article-title":"Impact of C-Reactive protein and liver frailty index on sarcopenia and poor outcome in liver transplant patients","author":"Wang","journal-title":"Clin Lab"},{"key":"key20260406110124_b152-or-55-5-09093","doi-asserted-by":"publisher","first-page":"eaan6282","DOI":"10.1126\/scisignal.aan6282","article-title":"C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis","volume":"10","author":"Yang","year":"2017","journal-title":"Sci Signal"},{"key":"key20260406110124_b153-or-55-5-09093","doi-asserted-by":"publisher","first-page":"830.e1","DOI":"10.1016\/j.jtct.2022.08.028","article-title":"Von willebrand factor and platelet levels before conditioning chemotherapy indicate bone marrow regeneration following autologous hematopoietic stem cell transplantation","volume":"28","author":"Radnay","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"key20260406110124_b154-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00277-021-04591-z","article-title":"N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution","volume":"100","author":"Jimenez-Zepeda","year":"2021","journal-title":"Ann Hematol"},{"key":"key20260406110124_b155-or-55-5-09093","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/CCI.19.00094","article-title":"Frailty in older adults with multiple myeloma: A study of US veterans","volume":"4","author":"Patel","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"key20260406110124_b156-or-55-5-09093","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.3390\/curroncol30060423","article-title":"The effects of second primary malignancies and frailty on overall survival and mortality in geriatric Turkish patients with multiple myeloma","volume":"30","author":"Ipek","year":"2023","journal-title":"Curr Oncol"},{"key":"key20260406110124_b157-or-55-5-09093","doi-asserted-by":"publisher","first-page":"110575","DOI":"10.1016\/j.clim.2025.110575","article-title":"Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation","volume":"279","author":"Zhang","year":"2025","journal-title":"Clin Immunol"},{"key":"key20260406110124_b158-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e70980","DOI":"10.1002\/cam4.70980","article-title":"Tregs at diagnosis as a potential biomarker for predicting high-risk functionality in newly diagnosed multiple myeloma","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med"},{"key":"key20260406110124_b159-or-55-5-09093","doi-asserted-by":"publisher","first-page":"189151","DOI":"10.1016\/j.bbcan.2024.189151","article-title":"Metabolomic biomarkers of multiple myeloma: A systematic review","volume":"1879","author":"Varzieva","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20260406110124_b160-or-55-5-09093","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/10408363.2025.2512466","article-title":"Advances in multiple myeloma blood-based monitoring and its clinical applications","volume":"62","author":"Tzasta","year":"2025","journal-title":"Crit Rev Clin Lab Sci"},{"key":"key20260406110124_b161-or-55-5-09093","doi-asserted-by":"publisher","first-page":"694331","DOI":"10.3389\/fonc.2021.694331","article-title":"Intratumor heterogeneity of MIF expression correlates with extramedullary involvement of multiple myeloma","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"key20260406110124_b162-or-55-5-09093","doi-asserted-by":"publisher","first-page":"bgaf033","DOI":"10.1093\/carcin\/bgaf033","article-title":"Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: Clinical significance and in vitro effects","volume":"46","author":"Li","year":"2025","journal-title":"Carcinogenesis"},{"key":"key20260406110124_b163-or-55-5-09093","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12967-022-03528-y","article-title":"TA-MSCs, TA-MSCs-EVs, MIF: Their crosstalk in immunosuppressive tumor microenvironment","volume":"20","author":"Zhang","year":"2022","journal-title":"J Transl Med"},{"key":"key20260406110124_b164-or-55-5-09093","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.75847","article-title":"Reduced splenic uptake on (68)Ga-Pentixafor-PET\/CT imaging in multiple myeloma-a potential imaging biomarker for disease prognosis","volume":"12","author":"Kraus","year":"2022","journal-title":"Theranostics"},{"key":"key20260406110124_b165-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2016.08.006","article-title":"Inflammation and frailty in the elderly: A systematic review and meta-analysis","volume":"31","author":"Soysal","year":"2016","journal-title":"Ageing Res Rev"},{"key":"key20260406110124_b166-or-55-5-09093","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11912-025-01639-5","article-title":"Current state of evidence on definitions and management of high-risk multiple myeloma","volume":"27","author":"Mohan Lal","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"key20260406110124_b167-or-55-5-09093","doi-asserted-by":"publisher","first-page":"2467499","DOI":"10.1080\/16078454.2025.2467499","article-title":"Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes","volume":"30","author":"Tang","year":"2025","journal-title":"Hematology"},{"key":"key20260406110124_b168-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e70268","DOI":"10.1002\/hem3.70268","article-title":"Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome","volume":"9","author":"Groen","year":"2025","journal-title":"Hemasphere"},{"key":"key20260406110124_b169-or-55-5-09093","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12603-020-1498-x","article-title":"Screening for and managing the person with frailty in primary care: ICFSR consensus guidelines","volume":"24","author":"Ruiz","year":"2020","journal-title":"J Nutr Health Aging"},{"key":"key20260406110124_b170-or-55-5-09093","first-page":"1186","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)","volume":"63","author":"Chinese Hematology","year":"2024","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key20260406110124_b171-or-55-5-09093","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1097\/BS9.0000000000000208","article-title":"Dynamic frailty-tailored therapy (DynaFiT): A proof-of-concept study in elderly patients with newly diagnosed multiple myeloma","volume":"6","author":"Dai","year":"2024","journal-title":"Blood Sci"},{"key":"key20260406110124_b172-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.3324\/haematol.2019.226407","article-title":"Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: Updated results of the EMN01 randomized trial","volume":"105","author":"Bringhen","year":"2020","journal-title":"Haematologica"},{"key":"key20260406110124_b173-or-55-5-09093","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1161\/01.CIR.0000089190.95415.9F","article-title":"New markers of inflammation and endothelial cell activation: Part I","volume":"108","author":"Szmitko","year":"2003","journal-title":"Circulation"},{"key":"key20260406110124_b174-or-55-5-09093","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-024-01115-6","article-title":"A roadmap towards improving outcomes in multiple myeloma","volume":"14","author":"Mohty","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Oncology Reports"],"original-title":[],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:01:31Z","timestamp":1775462491000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/or.2026.9093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":174,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.3892\/or.2026.9093","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}